Lisa A. Carey, MD
Dr. Lisa A. Carey is the Richardson and Marilyn Jacobs Preyer Distinguished Professor in Breast Cancer Research in the Department of Medicine at the University of North Carolina (UNC). She received her medical degree from the Johns Hopkins University School of Medicine where she remained for her residency in Internal Medicine followed by a fellowship in Medical Oncology and an advanced degree in Clinical Investigations. Dr. Carey joined the UNC faculty and Lineberger Comprehensive Cancer Center in 1998. Currently she is the Chief of the Division of Hematology and Oncology and Physician-in-Chief of the North Carolina Cancer Hospital. Dr. Carey has a longstanding research interest in the clinical application of laboratory findings in breast cancer. She designs and leads clinical trials of novel drugs and approaches, and is a close collaborator with several laboratory investigators and epidemiologists. In addition, Dr. Carey sits on numerous scientific advisory boards, She has served in many roles for the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research(AACR) and the NCI. She was awarded the Doris Duke Clinician Scientist Award in 1999, a Career Development Award from the National Cancer Institute (NCI) in 2000, was inducted into the Johns Hopkins Society of Scholars in 2008, was awarded the NCI Director's Service Award in 2011, and was named co-chair of the Alliance National Cooperate Group Breast Committee in 2016.
Stephen Frye, PhD
Dr. Stephen Frye is currently a Fred Eshelman Distinguished Professor and the Director of the Center for Integrative Chemical Biology and Drug Discovery (CICBDD) at the University of North Carolina at Chapel Hill (UNC). He is also co-director of the Molecular Therapeutics program in the Lineberger Comprehensive Cancer Center and the lead principal investigator for the North Carolina Comprehensive Chemical Biology Center, a UNC-based, National Cancer Institute (NCI) designated center that engages in oncology drug discovery. Prior to joining UNC to create the CICBDD in 2007, Dr. Frye was the world-wide vice president of Discovery Medicinal Chemistry (DMC) at GlaxoSmithKline (GSK). Dr. Frye led DMC for seven years, overseeing five departments and more than 200 chemists in the U.S. and U.K. developing global target-class chemical science for GSK. During his 20-year career at GSK, the teams/departments led by Dr. Frye successfully developed three FDA approved drugs: Avodart, a dual 5alpha-reductase inhibitor for treatment of benign prostatic hyperplasia, Tykerb, a dual erbB2/EGFR inhibitor for the treatment of metastatic breast cancer, and Pazopanib, a multi-targeted receptor tyrosine kinase inhibitor for the treatment of renal cell carcinoma and soft tissue sarcoma.As director of the Center for Integrative Chemical Biology and Drug Discovery at UNC, Dr. Frye plays a key role in translational research through collaborative drug discovery projects with other UNC faculty. In addition, his Center has initiated a program in the area of chemical biology of chromatin regulation with an emphasis on methyl-lysine reading domains. The first IND approved compound discovered in the Center, will enter clinical trials in 2018.
Timothy Heffernan, PhD
Dr. Timothy Heffernan is currently the Executive Director and Head of Oncology Research at the Institute for Applied Cancer Science (IACS), an integrated drug discovery and development unit within MD Anderson Cancer Center. He also serves as Director for the Center for Co-Clinical Trials, a translational biology platform focused on accelerating the pre-clinical evaluation of novel drugs to inform innovative clinical trials. Dr. Heffernan earned his degree in Cell and Molecular Pathology from the University of North Carolina at Chapel Hill and performed his postdoctoral training at the Dana Farber Cancer Institute and Harvard Medical School. His expertise lies in basic and translational cancer research, cancer genomics, and targeted oncology therapeutics. Dr. Heffernan currently manages the development of an advanced small molecule drug discovery portfolio coordinating research on programs from target identification through IND enabling studies and phase 1 clinical development. Prior to joining MD Anderson, Dr. Heffernan led target identification efforts at the Belfer Institute at Dana Farber Cancer Institute and also was a Senior Vice President at C4 Therapeutics Inc., where he managed the drug discovery and translational biology efforts to advance a portfolio of internal and partnered programs.
Peter Jackson, PhD
Dr. Jackson is a Professor of Microbiology and Immunology (Baxter Labs) and of Pathology at Stanford. He received a BA in Mathematics and Economics from Yale College before pursuing graduate work in Chemical Physics at the University of Chicago and receiving a PhD in Biophysics from Harvard University, completing his thesis on tyrosine kinase signaling with David Baltimore at MIT’s Whitehead Institute. Following postdoctoral work at UCSF with Mark Kirschner, studying the cell cycle, Dr. Jackson joined the faculty at Stanford in 1996. His laboratory studies focus on the biochemical and cell biological mechanisms controlling cell division, signaling and cancer, using proteomics and advanced imaging techniques. He has made a broad set of discoveries related to regulatory complexes and signaling in the cell cycle, ubiquitin-dependent proteolysis, cancer, signaling within the primary cilium and the link between cilia and human genetic diseases. Dr. Jackson spent from 2005 to 2013 at Genentech, where he was a Director and Staff Scientist focused on the discovery and validation of new targets for cancer chemotherapy. He is currently focused on understanding core mechanisms driving differentiation, especially in the context of ciliary signaling and using protein networks to find new core cancer driver pathways and explanations for unexplained human genetic diseases.
Jian Jin, PhD
Dr. Jian Jin is a world-renowned medicinal chemist with more than 20 years of experience in small-molecule drug discovery. He is currently the Mount Sinai Endowed Professor in Therapeutics Discovery, a Professor in the Department of Pharmacological Sciences, a Professor in the Department of Oncological Sciences, and the Director of the Mount Sinai Center for Therapeutics Discovery at the Icahn School of Medicine at Mount Sinai. Dr. Jin’s laboratory is a leader in discovering selective inhibitors of histone methyltransferases and biased ligands of G protein-coupled receptors, and a pioneer in developing novel degraders targeting oncogenic proteins. Dr. Jian Jin received a Bachelor’s of Science degree in chemistry from the University of Science and Technology of China in 1991 and a PhD in organic chemistry from the Pennsylvania State University in 1997. After completing a post-doctoral training at the Ohio State University, Dr. Jin joined GlaxoSmithKline as a medicinal chemist in 1998 and had been a manager of medicinal chemistry from 2003 to 2008. In 2008, Dr. Jin joined the Division of Chemical Biology and Medicinal Chemistry at the University of North Carolina at Chapel Hill (UNC) as an Associate Professor. He had also served as an Associate Director of Medicinal Chemistry in the Center for Integrative Chemical Biology and Drug Discovery at UNC from 2008 to 2014. Dr. Jin was recruited to the Icahn School of Medicine at Mount Sinai as a professor with tenure in 2014. Dr. Jin has published well over 100 peer-reviewed original research papers and delivered over 100 invited talks. He is also an inventor of 10 issued U.S. patents and 40 published PCT patent applications.
Michele Pagano, MD
Dr. Michele Pagano, MD, is the Chair of the Department of Biochemistry and Molecular Pharmacology and the May Ellen and Gerald Jay Ritter Professor of Oncology at the New York University School of Medicine, and an Investigator of the Howard Hughes Medical Institute. Dr. Pagano received his doctorate in Medicine and a specialty diploma in Molecular Endocrinology in 1990 from the Federico II University in his native Napoli, Italy. He was subsequently a post-doctoral fellow at EMBL, Heidelberg, Germany (1990-92), before co-founding Mitotix Inc. (1992-96). He joined the NYU School of Medicine in 1996. Dr. Pagano has received many prestigious grants including a MERIT Award (2006-2017) from the National Cancer Institute in recognition of his outstanding achievements in cancer biology. Dr. Pagano’s research focuses on the kinases and ubiquitylating enzymes that control cell proliferation and how deregulation of these machineries contribute to malignant transformation.
Yue Xiong, PhD
Dr. Xiong finished his undergraduate at Fudan University in 1982 and Ph.D from University of Rochester in 1989. After completing a Ph.D. Postdoctoral fellowship at Cold Spring Harbor Lab, from 1993 up to now, Dr. Xiong joined Department of Biochemistry & Biophysics at University of North Carolina at Chapel Hill as a William R. Kenan Professor. He was awarded Pew Scholar Award (1995), American Cancer Society Junior Faculty Research Award (1995), AACR-Gertrude B. Elion Cancer Research Awards (1999), UNC Hettleman Award for Scholarly Achievement (1999), UNC Battle Distinguished Cancer Research Award (2011), Elected Fellow, American Association for Advancement of Science (2012). To date, Dr. Xiong has published more than 160 research papers in peer-reviewed publication and granted two US patents.